Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
Last verified by NonDilute: 2026-04-29. Official notice and agency instructions control.
If you have promising early data for a cancer prevention or control intervention but need to validate design and feasibility before a full trial, this R34 planning grant de-risks your eventual Phase 3 study.
Report stale or inaccurate summary
What this is
This R34 grant funds planning grants (not full trials) for investigators who have preliminary evidence for a cancer prevention or control intervention but need to resolve critical unknowns about study design, feasibility, accrual, endpoints, or operational risks before launching a full clinical trial. The program targets cancer prevention/interception, behavioral health, screening, early detection, treatment-side-effect management, supportive care, and survivor outcomes. Eligible applicants range from small businesses to universities to nonprofits; most organization types can apply. Award amounts are not specified in this text.
Who can apply
Broad eligibility: nonprofits (501(c)(3) and non-501(c)(3)), small businesses, for-profit organizations, universities (public and private), state/local governments, tribal governments, and most other organization types. No geographic restriction mentioned. Solo individuals and very small teams may face institutional affiliation requirements typical of NIH grants.
Eligible applicant types
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Independent school districts
- Special district governments
- Public housing authorities/Indian housing authorities
- Small businesses
- State governments
- County governments
- Private institutions of higher education
- For profit organizations other than small businesses
- City or township governments
- Public and State controlled institutions of higher education
- Native American tribal organizations (other than Federally recognized tribal governments)
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Native American tribal governments (Federally recognized)
Full description — from the agency
The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.
Topics: cancer prevention clinical trials · feasibility studies oncology · trial planning grant · cancer screening research · cancer survivor care
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.